Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Jun;46(6):840-9.
doi: 10.1067/mjd.2002.121356.

A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines

J Alastair Carruthers  1 , Nicholas J Lowe, M Alan Menter, John Gibson, Marian Nordquist, Julie Mordaunt, Patricia Walker, Nina Eadie; BOTOX Glabellar Lines I Study Group
Affiliations
Clinical Trial

A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines

J Alastair Carruthers et al. J Am Acad Dermatol. 2002 Jun.

Abstract

Background: Botulinum toxin type A (BTX-A) is widely used for facial esthetics but is incompletely studied.

Objective: This study was conducted to evaluate the efficacy and safety of BTX-A treatment of glabellar lines.

Methods: Patients with moderate to severe glabellar lines at maximum frown received intramuscular injections of 20 U BTX-A (BOTOX, Allergan, Inc, Irvine, Calif) or placebo into 5 glabellar sites. Patients were followed up for 120 days after injection. Outcome measures were physician rating of glabellar line severity at maximum frown and rest, patient assessment of improvement, and vital sign and adverse event monitoring.

Results: Two hundred sixty-four patients were enrolled (BTX-A: 203, placebo: 61). There was a significantly greater reduction in glabellar line severity with BTX-A than with placebo (all measures, every follow-up visit; P <.022). The effect was maintained for many patients through day 120. There was a low occurrence (5.4%) of mostly mild blepharoptosis in the BTX-A group.

Conclusion: BTX-A injections are safe and effective in reducing the severity of glabellar lines.

PubMed Disclaimer

Publication types

MeSH terms

Substances